ISR: UPMC Study Reports Isoray’s Cesium-131 Prostate Treatment Provides Strong Cancer Control with Lower Side Effects.
Cesium-131 Seed Brachytherapy Offers Extremely High Efficacy Compared to Other Isotopes or Treatment Modalities Used in Treating Prostate Cancer, with the Advantage of Rapid Return to Pre-Treatment Urinary Function, and at Lower Cost Richland, WA (January 20, 2015) – IsoRay Inc. (NYSE:ISR), a medical technology company and innovator in brachytherapy and medical isotope… Read more »
Shares of IsoRay Inc opened today at $1.36 and are currently trading up at $1.38. ISR has a 1-year high of $3.77 and a 1-year low of $0.66. The stock’s 50-day moving average is $1.58 and it’s 200-day moving average is $1.96.
On the ratings front, IsoRay Inc has been the subject of a number of recent research reports. In a report published on January 13, analyst Jason Kolbert from Maxim Group reiterated a Buy rating on ISR, with a price target of $5, which implies an upside of 267.6% from current levels.
IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes.